Evidence map›Paper›PMID 33588914›Full record

ArticleCritical care (London, England)2021

Deploying unsupervised clustering analysis to derive clinical phenotypes and risk factors associated with mortality risk in 2022 critically ill patients with COVID-19 in Spain.

Alejandro Rodríguez, Manuel Ruiz-Botella, Ignacio Martín-Loeches, María Jimenez Herrera, Jordi Solé-Violan, Josep Gómez, María Bodí, Sandra Trefler, Elisabeth Papiol, Emili Díaz and 22 more

Registry-linked trialAbstract read
In one paragraph

Article in Critical care (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04948242 (Epidemiologic, Clinical Characteristics and Risk Factors of Critical Ill Patients Admitted to the ICU for Severe Acute Respiratory Syndrome Coronavirus 2 Infection), which is not on this map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04948242 unknown statusnot on this map

Epidemiologic, Clinical Characteristics and Risk Factors of Critical Ill Patients Admitted to the ICU for Severe Acute Respiratory Syndrome Coronavirus 2 Infection (COVID-19)

Typeobservational_patient_registrySponsorHospital Universitari Joan XXIII de Tarragona.Ran2019 to 2023Enrolled5,000ConditionsSARS-CoV2 Infection
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Observational
  13. Review
  14. Article
  15. Article
  16. Observational
  17. Article
  18. Article
  19. Review
  20. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Alejandro RodríguezICU Hospital Universitario Joan XXIII/IISPV/URV, Mallafre Guasch 4, 43007, Tarragona, Spain. ahr1161@yahoo.es.ORCID 0000-0001-8828-5984
Manuel Ruiz-BotellaTarragona Health Data Research Working Group (THeDaR), ICU Hospital Universitario Joan XXIII, Tarragona, Spain.
Ignacio Martín-LoechesDepartment of Intensive Care Medicine, Multidisciplinary Intensive Care Research Organization (MICRO), St. James's Hospital, Dublin, Ireland.
María Jimenez HerreraDean Nursing Faculty, Universitat Rovira i Virgili, Tarragona, Spain.
Jordi Solé-ViolanICU Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Josep GómezTarragona Health Data Research Working Group (THeDaR), ICU Hospital Universitario Joan XXIII, Tarragona, Spain.
María BodíICU Hospital Universitario Joan XXIII/IISPV/URV, Mallafre Guasch 4, 43007, Tarragona, Spain.
Sandra TreflerICU Hospital Universitario Joan XXIII/IISPV/URV, Mallafre Guasch 4, 43007, Tarragona, Spain.
Elisabeth PapiolICU Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Emili DíazICU Hospital Parc Tauli, Sabadell, Spain.
Borja SuberviolaICU Hospital Marqués de Valdecilla, Santander, Spain.
Montserrat VallverduICU Hospital Universitario Arnau de Vilanova, Lleida, Spain.
Eric Mayor-VázquezICU Hospital Verge de la Cinta, Tortosa, Spain.
Antonio Albaya MorenoICU Hospital Universitario de Guadalajara, Guadalajara, Spain.
Alfonso Canabal BerlangaICU Hospital de La Princesa, Madrid, Spain.
Miguel SánchezICU Hospital Clinico San Carlos, Madrid, Spain.
María Del Valle OrtízICU Hospital Universitario de Burgos, Burgos, Spain.
Juan Carlos BallesterosICU Hospital Clínico de Salamanca, Salamanca, Spain.
Lorena Martín IglesiasICU Hospital Universitario Central de Asturias, Oviedo, Spain.
Judith Marín-CorralICU Hospital del Mar, Barcelona, Spain.
Esther López RamosICU Hospital Príncipe de Asturias, Alcalá de Henares, Spain.
Virginia Hidalgo ValverdeICU Hospital Complejo Asistencial de Segovia, Segovia, Spain.
Loreto Vidaur Vidaur TelloICU Hospital Universitario de Donostia, Donosia, Spain.
Susana Sancho ChinestaICU Hospital Universitario y Politécnico La Fe, Valencia, Spain.
Francisco Javier Gonzáles de MolinaICU Hospital Universitario de Terrasa, Terrasa, Spain.
Sandra Herrero GarcíaICU Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
Carmen Carolina Sena PérezICU Hospital Nuestra Señora del Prado, Talavera de la Reina, Spain.
Juan Carlos Pozo LaderasICU Hospital Universitario Reina Sofía, Córdoba, Spain.
Raquel Rodríguez GarcíaICU Complejo Hospitalario Universitario a Coruña, A Coruña, Spain.
Angel EstellaICU Hospital Universitario de Jerez, Jerez de la Frontera, Spain.
Ricard FerrerICU Hospital Universitario Vall d'Hebron, Barcelona, Spain.
COVID-19 SEMICYUC Working Group

Funding

Fundación Privada Barri Casanovas RBCF/2019
6 · The paper itself

Abstract

backgroundThe identification of factors associated with Intensive Care Unit (ICU) mortality and derived clinical phenotypes in COVID-19 patients could help for a more tailored approach to clinical decision-making that improves prognostic outcomes.

methodsProspective, multicenter, observational study of critically ill patients with confirmed COVID-19 disease and acute respiratory failure admitted from 63 ICUs in Spain. The objective was to utilize an unsupervised clustering analysis to derive clinical COVID-19 phenotypes and to analyze patient's factors associated with mortality risk. Patient features including demographics and clinical data at ICU admission were analyzed. Generalized linear models were used to determine ICU morality risk factors. The prognostic models were validated and their performance was measured using accuracy test, sensitivity, specificity and ROC curves.

resultsThe database included a total of 2022 patients (mean age 64 [IQR 5-71] years, 1423 (70.4%) male, median APACHE II score (13 [IQR 10-17]) and SOFA score (5 [IQR 3-7]) points. The ICU mortality rate was 32.6%. Of the 3 derived phenotypes, the A (mild) phenotype (537; 26.7%) included older age (< 65 years), fewer abnormal laboratory values and less development of complications, B (moderate) phenotype (623, 30.8%) had similar characteristics of A phenotype but were more likely to present shock. The C (severe) phenotype was the most common (857; 42.5%) and was characterized by the interplay of older age (> 65 years), high severity of illness and a higher likelihood of development shock. Crude ICU mortality was 20.3%, 25% and 45.4% for A, B and C phenotype respectively. The ICU mortality risk factors and model performance differed between whole population and phenotype classifications.

conclusionThe presented machine learning model identified three clinical phenotypes that significantly correlated with host-response patterns and ICU mortality. Different risk factors across the whole population and clinical phenotypes were observed which may limit the application of a "one-size-fits-all" model in practice.

Indexed as

AgedCluster AnalysisCOVID-19Critical IllnessFemaleHumansMaleMiddle AgedPhenotypeRisk AssessmentRisk FactorsSpainMachine learningPhenotypesPrognosisRisk factorsSevere SARS-CoV-2 infection

Identifiers

PMID33588914
PMCPMC7883885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.